Epividian advances the mission of medicine by developing novel technologies and empowering clinical practice, clinical research, academic, public health and regulatory efforts.
We are healthcare data and technology experts with tailored solutions in:
Clinical practice and clinical research
Population and disease management
MIPS & Ryan White Reporting
The Epividian technology platform and observational database program has been utilized by many physicians, epidemiologists and researchers to produce dozens of papers, abstracts and presentations.
Meet Our Team
Bernie Stooks is the Director of Data Management and Reporting for Epividian. With over 14 years of IT experience, as well as the last 10 years dedicated in healthcare, Bernie brings a wide-range of technical leadership capabilities to Epividian. Prior to joining Epividian, Bernie architected and led a multi-team Warehouse/BI project for an S&P 500 Company that integrated disparate data stores into a large federated enterprise warehouse. Bernie has been instrumental in the redesign of the Epividian databases leading to improved data quality and more efficient processing. Bernie is currently engaged in the design and development of the Epividian Reporting Portal as well as integrating a natural language processing solution that will enhance the classification and entity resolution capabilities of CHORUS and OPERA.
Gregory Fusco is Chief Executive Officer and Chief Medical Officer at Epividian. Mr. Fusco studied microbiology at the University of Michigan, epidemiology at the University of Michigan School of Public Health and medicine at the Michigan State University College of Human Medicine. He trained in anatomic pathology at the University of Pittsburgh. His epidemiology experience spanned both government and industry appointments. He was a site coordinator (Detroit) for the Adult Spectrum of Disease in HIV Study, a national Centers for Disease Control and Prevention sponsored study. This study contributed to the 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. He has 18 years of experience in the pharmaceutical industry leading Phase 1, 2, 3, and 4 clinical trials in multiple therapeutic disciplines as well as leading epidemiology and outcomes research groups and pharmacoepidemiologic, pharmacovigilance, risk management and signal detection efforts in development programs for both small molecules and biologics. His therapeutic development and life cycle management experience includes Infectious Disease (HIV/HCV), gastrointestinal disease (UC/CD, EE, GERD), metabolic disease (diabetes), cardiovascular disease (hypertension), dermatologic disease (psoriasis), and renal & hematologic disease (anemia of CKD). Well published in multiple therapeutic disciplines, he continues to develop systems for the improvement of medical practice, clinical development and adverse event management and signaling. Additional efforts include the development and identification of biomarker profiles utilizing observational (big data) databases to assist in the medical management of patients and the design and conduct of clinical trials.
Jennifer Fusco is Chief Science Officer at Epividian. She studied biology at the University of Michigan and epidemiology at the College of Human Medicine at Michigan State University. Jennifer heads the scientific operations for Epividian and has been working in and/or consulting for the pharmaceutical industry and academia for the past 18 years. Her research focus has been mainly in HIV working with population-level, observational databases. As a founding member of the CHORUS (Collaborations in HIV Outcomes Research in the US) database at GlaxoWellcome/ GlaxoSmithKline, she has consulted on specific research efforts as well as the design and development of database architectural and analysis standards. Her clients have included GlaxoWellcome, GlaxoSmithKline, Boehringer-Ingelheim, Hoffmann-La Roche, University of North Carolina School of Public Health, the Veterans Administration and Yale University. She is well published with experience in the CHORUS database, the OPERA database, the CASCADE (Concerted Action on SeroConversion to AIDS and Death in Europe) database and the VACS (Veterans Aging Cohort Study) database as well as multi-database global collaborations such as the ARTCC and PLATO research collaborative groups.
Rodney Mood is Chief Operating Officer at Epividian and has over 20 years in managerial and technical roles in healthcare IT, automation, and data analytics. Rodney was an original CHORUS team member at Glaxo-Wellcome/GlaxoSmithKline where he managed new EHR implementations and training programs for caregivers and CHORUS collaborators. Rodney previously worked as a software developer at HealthMatics to design and develop their Electronic Health Record system. As Epividian COO, Rodney manages the integration of new clinics and researchers into the CHORUS & OPERA programs in addition to providing product strategy and design for Epividian customers and research partners.
Ted Ising is Chief Technology Officer at Epividian and has over 20 years of experience architecting solutions and new technologies to solve complex problems that include the areas of disease management, observational databases, electronic health records, and predictive diagnostic medical devices. He previously worked at Allscripts, a leading provider in Electronic Health Records software, where he helped develop and operate databases and multi-purpose interfaces to exchange patient health information. Ted is also an original member of the CHORUS team at Glaxo-Wellcome/GlaxoSmithKline where he designed and developed databases and software for the full data management lifecycle of the CHORUS system. As Epividian CTO, Ted leads the effort to expand the capabilities of the CHORUS and OPERA platforms with new technologies and user-centered solutions.
Laurence Brunet is an Director of Epidemiology at Epividian. She is a clinical epidemiologist with expertise in the study of HIV comorbidities and unintended effects of drugs in HIV and HIV/HCV co-infected populations. Laurence obtained her MSc (2010) and PhD (2015) degrees in Epidemiology from McGill University, where she conducted studies on tuberculosis in South Africa, and on the impact of illicit and prescribed drug use on the liver in HIV/HCV co-infected patients in Canada. She moved to North Carolina in 2015 to work as a Postdoctoral Research Associate at the Institute for Global Health and Infectious Diseases of the University of North Carolina at Chapel Hill. There, she led projects on HIV comorbidities, HIV treatment, opioid use, and HCV therapy. Laurence joined Epividian in 2017, where she is responsible for the design, conduct, analysis and result dissemination of observational studies using the OPERA database.